In this slide show we highlight some of the top news on gynecologic cancers in 2017, including studies on surgery for cervical and ovarian cancer, the FDA approval of niraparib, and more.
Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers
Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.
Empowering Awareness to Address Rising Gynecological Cancer Incidence
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Uterine Transposition Surgery Improves QOL Through Fertility Preservation
A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.
Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Uterine Serous Carcinoma Tumors Appear More Aggressive in Black Populations
PAX8, a marker for aggressive disease in numerous cancer types, was more highly expressed in Black patients with uterine serous carcinoma.
Envafolimab Combo Yields Enduring Responses in Advanced Endometrial Cancer
Data support subcutaneous envafolimab plus lenvatinib as a promising new therapy option in advanced endometrial cancer.